Get startedLog in
    Picture of Sichuan Kelun-Biotech Biopharmaceutical logo

    6990 — Sichuan Kelun-Biotech Biopharmaceutical News Story

    0.000.00%
    hk flag iconLast trade - 00:00
    HealthcareSpeculativeLarge CapHigh Flyer
    All News

    Brief: Kelun-Biotech's Sac-TMT + Pembrolizumab Improves Survival In Late-Stage China Trial

    Picture of Sichuan Kelun-Biotech Biopharmaceutical logoSichuan Kelun-Biotech Biopharmaceutical
    21/05/2026 22:03
    May 22 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd 6990.HK:

SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL-SAFETY PROFILE OF SAC-TMT + PEMBROLIZUMAB GENERALLY MANAGEABLE, CONSISTENT WITH SAFETY PROFILE OF COMPONENTS

SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL: SACITUZUMAB TIRUMOTECAN + PEMBROLIZUMAB EXTENDED PFS VERSUS PEMBROLIZUMAB ALONE IN PHASE 3 LUNG CANCER TRIAL

SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL: OBJECTIVE RESPONSE RATE 70.2% WITH SAC-TMT PLUS PEMBROLIZUMAB VERSUS 42.0% WITH PEMBROLIZUMAB ALONE

Further company coverage: 6990.HK

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Sichuan Kelun-Biotech Biopharmaceutical

    See all news